Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.01 is 764% above its 3-year average of 0.00, near the high end of its 3-year range (0.00–0.01).
As of the fiscal period ended Tuesday, June 30, 2026. 161.27% above its 12-month average of 0.00.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.01.
DEBT TO EQUITY RATIO
0.01
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+161.27%
CURRENT VS 3Y AVG
+677.38%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 633 covered companies
CURRENT VS SECTOR MEDIAN
-93.72%
vs the sector median at left
MBX Biosciences, Inc. Common Stock
Market Cap
$2.72B
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
N/A
Market Cap
$2.70B
Debt to Equity Ratio
1.30
TTM Avg
1.02
3Y Avg
0.78
5Y Avg
0.91
Market Cap
$2.69B
Debt to Equity Ratio
5.24
TTM Avg
7.79
3Y Avg
7.79
5Y Avg
4.92
Market Cap
$2.82B
Debt to Equity Ratio
1.67
TTM Avg
1.63
3Y Avg
1.85
5Y Avg
1.39
Market Cap
$2.63B
Debt to Equity Ratio
0.23
TTM Avg
0.23
3Y Avg
0.22
5Y Avg
0.25
Market Cap
$2.62B
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MBX Biosciences, Inc. Common Stock (MBX) | $2.72B | 0.01 | 0.00 | 0.00 | N/A |
| Precigen, Inc. (PGEN)vs › | $2.74B | 2.26 | 2.42 | 1.33 | 1.63 |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.70B | 1.30 | 1.02 | 0.78 | 0.91 |
| Neogen Corporation (NEOG)vs › | $2.69B | 0.38 | 0.41 | 0.35 | 0.23 |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 5.24 | 7.79 | 7.79 | 4.92 |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 0.14 | 0.17 | 0.17 | 0.17 |
| TransMedics Group, Inc. (TMDX)vs › | $2.82B | 1.67 | 1.63 | 1.85 | 1.39 |
| Beam Therapeutics Inc. (BEAM)vs › | $2.63B | 0.23 | 0.23 | 0.22 | 0.25 |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.62B | 0.00 | 0.00 | 0.00 | 0.00 |
| Privia Health Group, Inc. (PRVA)vs › | $2.59B | 0.01 | 0.01 | 0.01 | 0.07 |
Debt/Equity
0.01
Current Ratio
18.08
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.01 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.01 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
